Conclusion A new era for obesity treatment has commenced where pharmacotherapy with combinations of entero-pancreatic hormones approach the WL efficacy of bariatric surgery
Maxler GTI
However, 2024 clinical practice guidelineswhich were endorsed by the American Society of Anesthesiologists and several other professional medical societiesexplain that this blanket recommendation is not necessary
A phase 2 trial found that roughly 35% of the weight loss with semaglutide came from lean mass
One study found that mice treated with 5-Amino-1MQ had significantly lower body weight, smaller fat cells, and less overall fat mass than untreated mice , despite no difference in food intake
Campbell JM, Stephenson MD, De Courten B, Chapman I, Bellman SM, Aromataris E